CSL Ltd Annual Report 2019

Base Fractionation: Broadmeadows, Kankakee, Marburg Project Protinus: Bern Influenza Vaccine Manufacturing: Holly Springs A US$140 million expansion in manufacturing will allow Seqirus to increase capacity for formulation, fill and finish manufacturing of cell-based and adjuvanted influenza vaccines for global markets. In order to meet the high demand for immunoglobulin products, CSL Behring is expanding its production capacity in Bern. CSL Behring is investing CHF 300 million in the project which has created around 50 new jobs in the city of Bern. This expansion will allow an additional 90,000 patients a year to live an improved quality of life. We continue our base fractionation capacity expansion projects across our facilities in Broadmeadows, Kankakee and Marburg. These investments will help to meet the future global demand for our products by expanding production capacity and supporting end- to-end manufacturing of plasma-derived therapies. CSL Limited Annual Report 2019 23